DALLAS and FORT WORTH, Texas, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that management will participate in two upcoming conferences in December.
- Management will be available for one-on-one meetings at the Global Mizuho Investor Conference (MIC) 2017 on Tuesday, December 5, 2017 in New York, NY.
- Vipin K. Garg, Ph.D., President and CEO, will participate in a fireside chat at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017 at 3:00 p.m. ET in New York, NY.
A live webcast of the BMO presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex®1, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is available at www.neostx.com.
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts:
| Richard Eisenstadt | Sarah McCabe | |
| Chief Financial Officer | Vice President | |
| Neos Therapeutics | Stern Investor Relations, Inc. | |
| (972) 408-1389 | (212) 362-1200 | |
| reisenstadt@neostx.com | sarah@sternir.com |